MSF Field Research > 1 Published Research and Commentary > HIV/AIDS > Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa.

Please use this identifier to cite or link to this item:     LinkedIn     Citeulike     Connotea     Facebook     Stumble it!

Download this article:
View/Open File Description Size Format
Khaylelitsha AIDS 2010.pdf424KbAdobe PDF

Title: Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa.
Authors: Boulle, Andrew
Van Cutsem, Gilles
Hilderbrand, Katherine
Cragg, Carol
Abrahams, Musaed
Mathee, Shaheed
Ford, Nathan
Knight, Louise
Osler, Meg
Myers, Jonny
Goemaere, Eric
Coetzee, David
Maartens, Gary
Affiliation: School of Public Health and Family Medicine, University of Cape Town, Anzio Road, Cape Town, South Africa.
Citation: Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. 2010, 24 (4):563-72 AIDS
Journal: AIDS (London, England)
Issue Date: 20-Feb-2010
DOI: 10.1097/QAD.0b013e328333bfb7
PubMed ID: 20057311
Abstract: OBJECTIVES: We report on outcomes after 7 years of a community-based antiretroviral therapy (ART) programme in Khayelitsha, South Africa, with death registry linkages to correct for mortality under-ascertainment. DESIGN: This is an observational cohort study. METHODS: Since inception, patient-level clinical data have been prospectively captured on-site into an electronic patient information system. Patients with available civil identification numbers who were lost to follow-up were matched with the national death registry to ascertain their vital status. Corrected mortality estimates weighted these patients to represent all patients lost to follow-up. CD4 cell count outcomes were reported conditioned on continuous virological suppression. RESULTS: Seven thousand, three hundred and twenty-three treatment-naive adults (68% women) started ART between 2001 and 2007, with annual enrolment increasing from 80 in 2001 to 2087 in 2006. Of 9.8% of patients lost to follow-up for at least 6 months, 32.8% had died. Corrected mortality was 20.9% at 5 years (95% confidence interval 17.9-24.3). Mortality fell over time as patients accessed care earlier (median CD4 cell count at enrolment increased from 43 cells/microl in 2001 to 131 cells/microl in 2006). Patients who remained virologically suppressed continued to gain CD4 cells at 5 years (median 22 cells/microl per 6 months). By 5 years, 14.0% of patients had failed virologically and 12.2% had been switched to second-line therapy. CONCLUSION: At a time of considerable debate about future global funding of ART programmes in resource-poor settings, this study has demonstrated substantial and durable clinical benefits for those able to access ART throughout this period, in spite of increasing loss to follow-up.
Language: en
ISSN: 1473-5571
Rights: Published by Wolters Kluwer Lippincott Williams & Wilkins - Archived on this site by kind permission Wolters Kluwer
Appears in topics: HIV/AIDS

Related articles on PubMed
Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa.
Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, Labatala V, Reuter H, Ntwana N, Goemaere E
2004 Apr 9
Mortality and loss to follow-up among HAART initiators in rural South Africa.
MacPherson P, Moshabela M, Martinson N, Pronyk P
2009 Jun
Effectiveness of highly active antiretroviral therapy administered by general practitioners in rural South Africa.
Barth RE, van der Meer JT, Hoepelman AI, Schrooders PA, van de Vijver DA, Geelen SP, Tempelman HA
2008 Oct
Effectiveness of antiretroviral treatment in a South African program: a cohort study.
Fairall LR, Bachmann MO, Louwagie GM, van Vuuren C, Chikobvu P, Steyn D, Staniland GH, Timmerman V, Msimanga M, Seebregts CJ, Boulle A, Nhiwatiwa R, Bateman ED, Zwarenstein MF, Chapman RD
2008 Jan 14
See all 182 articles

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.


OR Logo Powered by Open Repository | Cookies


MSF logo MSF Field Research

Aug 29, 2015